CXCL13 antibody for the treatment of autoimmune disorders

BMC Immunology

Volumn 16, Issue 1, 2015, Pages

  Klimatcheva, Ekaterina ^a   Pandina, Tracy ^a   Reilly, Christine ^a   Torno, Sebold ^a   Bussler, Holm ^a   Scrivens, Maria ^a   Jonason, Alan ^a   Mallow, Crystal ^a   Doherty, Michael ^a   Paris, Mark ^a   Smith, Ernest S ^a   Zauderer, Maurice ^a  

^a VACCINEX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR5; CHIMERIC ANTIBODY; CXCL13 CHEMOKINE; ETANERCEPT; HAPTEN; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY 5261; UNCLASSIFIED DRUG; 4-HYDROXY-5-NITROPHENYL ACETIC ACID; BLOCKING ANTIBODY; CXCR5 PROTEIN, HUMAN; HEMOCYANIN; HYBRID PROTEIN; IMMUNOGLOBULIN G; KEYHOLE-LIMPET HEMOCYANIN; NITROPHENOL; PHENYLACETIC ACID DERIVATIVE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL MIGRATION; CHEMOTAXIS; CONJUGATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ENDOCYTOSIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GERMINAL CENTER; HUMAN; HUMAN TISSUE; HYBRIDOMA; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN LIGHT CHAIN GENE; IN VITRO STUDY; IN VIVO STUDY; LYMPH FOLLICLE; LYMPHOCYTE HOMING; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; NORMAL HUMAN; RAT; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SPLEEN CELL; TARGET ORGAN; TH17 CELL; ANIMAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; CELL MOTION; CHEMISTRY; DBA MOUSE; DISEASE MODEL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FOLLICULAR DENDRITIC CELL; GENETIC ENGINEERING; IMMUNOLOGY; IMMUNOTHERAPY; MACROPHAGE; METABOLISM; PROCEDURES;

ANIMALS; ANTIBODIES, BLOCKING; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CXCL13; DENDRITIC CELLS, FOLLICULAR; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENETIC ENGINEERING; GERMINAL CENTER; HEMOCYANIN; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MULTIPLE SCLEROSIS; NITROPHENOLS; PHENYLACETATES; RECEPTORS, CXCR5; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TH17 CELLS;

EID: 84923911683     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/s12865-015-0068-1     Document Type: Article

References (66)

1. Gunn MD, Ngo VN, Ansel KM, Ekland EH, Cyster JG, Williams LT. AB-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature. 1998;391:799-803.
2. Carlsen HS, Baekkevold ES, Morton HC, Haraldsen G, Brandtzaeg P. Monocyte-like and mature macrophages produce CXCL13 (B-cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood. 2004;104(10):3021-7.
3. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med. 1998;187:655-60.
4. FÖrster R, Emrich T, Kremmer E, Lipp M. Expression of the G-protein-coupled receptor BLR1 defines mature, recirculating B cells and a subset of T-helper memory cells. Blood. 1994;84:830-40.
5. Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG. Follicular helper T cells: lineage and location. Immunity. 2009;30:324-35.
6. Ansel KM, McHeyzer-Williams LJ, Ngo VN, McHeyzer-Williams MG, Cyster JG. In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines. J Exp Med. 1999;190:1123-34.
7. Lim HW, Lee J, Hillsamer P, Kim CH. Human Th17 cells share major trafficking receptors with both polarized effector T Cells and FOXP3+ regulatory T Cells. J Immunol. 2008;180:122-9.
8. Lim HW, Hillsamer P, Kim CH. Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J Clin Invest. 2004;114(11):1640-9.
9. FÖrster R, Emrich T, Kremmer E, Lipp M. Expression of the G-protein-coupled receptor BLR1 defines mature, recirculating B Cells and a subset of T-helper memory cells. Blood. 1994;84(3):830-40.
10. Jenh CH, Cox MA, Hipkin W, Lu T, Pugliese-Sivo C, Gonsiorek W, et al. Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor. Cytokine. 2001;15(3):113-21.
11. FÖrster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M. A putative chemokine receptor, BLR1, directs B-cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell. 1996;87:1037-47.
12. Ansel KM, Ngo VN, Hyman PL, Luther SA, FÖrster R, Sedgwick JD, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature. 2000;406:309-14.
13. Dighiero G, Lymberi P, Holmberg D, Lundquist I, Coutinho A, Avrameas S. High frequency of natural autoantibodies in normal newborn mice. J Immunol. 1985;134(2):765-71.
14. Cote RJ, Morrissey DM, Houghton AN, Thomson TM, Daly ME, Oettgen HF, et al. Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens. Proc Natl Acad Sci U S A. 1986;83:2959-63.
15. Vinuesa CG, Sanz I, Cook MC. Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol. 2009;9(12):845-57.
16. Louten J, Boniface K, de Waal Malefyt R. Development and function of Th17 cells in health and disease. J Allergy Clin Immunol. 2009;123:1004-11.
17. Peck A, Mellins ED. Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin Immunol. 2009;132(3):295-304.
18. Tripodo C, Gri G, Piccaluga PP, Frossi B, Guarnotta C, Piconese S, et al. Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol. 2010;177(2):792-802.
19. Takagi R, Higashi T, Hashimoto K, Nakano K, Mizuno Y, Okazaki Y, et al. B cell chemoattractant CXCL13 is preferentially expressed by human Th17 cell clones. J Immunol. 2008;181:186-9.
20. Patakas A, Benson RA, Withers DR, Conigliaro P, McInnes IB, Brewer JM, et al. Th17 effector cells support B cell responses outside of germinal centres. PLoS One. 2012;7(11):1-14.
21. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 2009;65(5):499-509.
22. Romme Christensen J, BÖrnsen L, Ratzer R, Piehl F, Khademi M, Olsson T, et al. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS One. 2013;8(3):e57820.
23. Corcione A, Casazza S, Ferretti E, Giunti D, Zappia E, Pistorio A, et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A. 2004;101(30):11064-9.
24. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centres in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14:164-74.
25. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130:1089-104.
26. Brettschneider J, Czerwoniak A, Senel M, Fang L, Kassubek J, Pinkhardt E, et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One. 2010;5(8):e11986.
27. Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor, receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum. 2008;58(8):2257-67.
28. Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, Lipsky PE, et al. Lymphoid chemokine B cell-attracting chemokine -1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol. 2001;166:650-5.
29. Schmutz C, Hulme A, Burman A, Salmon M, Ashton B, Buckley C, et al. Chemokine receptors in the rheumatoid synovium: upregulation of CXCR5. Arthritis Res Ther. 2005;7:R217-29.
30. HjelmstrÖm P. Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. J Leukoc Biol. 2001;69:331-9.
31. Armengol MP, Cardoso-Schmidt CB, Fernández M, Ferrer X, Pujol-Borrell R, Juan M. Chemokines determine local lymphoneogenesis and a reduction of circulating CXCR4+ T and CCR7+ B and T lymphocytes in thyroid autoimmune diseases. J Immunol. 2003;170:6320-8.
32. Nakashima Y, Isomoto H, Matsushima K, Yoshida A, Nakayama T, Nakayama M, et al. Enhanced expression of CXCL13 in human helicobacter pylori-associated gastritis. Dig Dis Sci. 2011;56(10):2887-94.
33. Mazzucchelli L, Blaser A, Kappeler A, Schärli P, Laissue JA, Baggiolini M, et al. BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J Clin Invest. 1999;104(10):R49-54.
34. Steinmetz OM, Panzer U, Kneissler U, Harendza S, Lipp M, Helmchen U, et al. BCA-1/CXCL13 expression is associated with CXCR5-positive B-cell cluster formation in acute renal transplant rejection. Kidney Int. 2005;67:1616-21.
35. Barone F, Bombardieri M, Rosado MM, Morgan PR, Challacombe SJ, De Vita S, et al. CXCL13, CCL21 and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol. 2008;180:5130-40.
36. Henneken M, DÖrner T, Burmester GR, Berek C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2005;7:R1001-13.
37. Meraouna A, Cizeron-Clairac G, Panse RL, Bismuth J, Truffault F, Tallaksen C, et al. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood. 2006;108(2):432-40.
38. Kramer JM, Klimatcheva E, Rothstein TL. CXCL13 is elevated in SjÖgren's syndrome in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol. 2013;94(5):1079-89.
39. Neel NF, Schutyser E, Sai J, Fan GH, Richmond A. Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev. 2005;16:637-58.
40. Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 2007;110:3316-25.
41. Arnold CN, Campbell DJ, Lipp M, Butcher EC. The germinal center response is impaired in the absence of T-cell expressed CXCR5. Eur J Immunology. 2007;37:100-9.
42. Holmdahl R, Andersson ME, Goldschmidt TJ, Jansson L, Karlsson M, MalmstrÖm V, et al. Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity. APMIS. 1989;97(7):575-84.
43. Zheng B, Ozen Z, Zhang X, De Silva S, Marinova E, Guo L, et al. CXCL13 neutralization reduces the severity of collagen-induced arthritis. Arthritis Rheum. 2005;52(2):620-6.
44. Finch D, Ettinger R, Karnell J, Ronald Herbst R, Sleeman MA. Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease. Eur J Clin Invest. 2013;43(5):501-9.
45. Stromnes IM, Goverman JM. Passive induction of experimental allergic encephalomyelitis. Nat Protoc. 2006;1(4):1952-60.
46. Stromnes IM, Goverman JM. Active induction of experimental allergic encephalomyelitis. Nat Protoc. 2006;1(4):1810-9.
47. Bagaeva LV, Rao P, Powers JM, Segal BM. CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis. J Immunol. 2006;176(12):7676-85.
48. Jäger A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol. 2009;18:7169-77.
49. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, et al. T helper type 1 and 17 cell determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010;4(16):406-12.
50. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010;162(1):1-11.
51. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton SE, Franz B, et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity. 2011;35(6):986-96.
52. Sellebjerg F, Bornsen L, Khademi M, Krakauer M, Olsson T, Frederiksen JL, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009;73:2003-10.
53. Lee HT, Shiao YM, Wu TH, Chen WS, Hsu YH, Tsai SF, et al. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J Rheumatol. 2010;37(1):45-52.
54. Bugatti S, Manzo A, Benaglio F, Klersy C, Vitolo B, Todoerti M, et al. Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Res Ther. 2012;14(1):R34.
55. Klarenbeek A, Maussang D, Blanchetot C, Saunders M, van der Woning S, Smit M, et al. Targeting chemokines and chemokine receptors with antibodies. Drug Discov Today Technol. 2012;9(4):e237-44.
56. Yellin M, Paliienko I, Balanescu A, Ter-Vartanian S, Tseluyko V, Xu LA, et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64(6):1730-9.
57. Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomized study. Gut. 2014;63(3):442-50.
58. Safety Information and Side Effects of Enbrel (Etanercept) [ http://www.enbrel.com/possible-side-effects.jspx ]
59. Brur-Waldert V, Sturner K, Kolster M, Wolthausen J, Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain. 2009;132(Pt 12):3329-41.
60. Darlington PJ, Touil T, Doucet J-S, Gaucher D, Zeidan J, Gauchat D, et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol. 2013;73(3):341-54.
61. Begum-Hague S, Sharma A, Kasper IR, Foureau DM, Mielcarz DW, Haque A, et al. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2008;204(1-2):58-65.
62. Aharoni R, Eilam R, Stock A, Vainshtein A, Shezen E, Gal H, et al. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. J Neuroimmunol. 2010;225(1-2):100-11.
63. Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, Kappos L, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology. 2010;75(5):403-10.
64. Ramgolam VS, Markovic-Plese S. Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis. Endocr Metab Immune Disord Drug Targets. 2010;10(2):161-7.
65. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomized, dose-ranging study. Lancet Neurol. 2008;7(9):796-804.
66. Finch DK, Ettinger R, Karnell JL, Herbst R, Sleeman MA. Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease. Eur J Clin Invest. 2013;43(5):501-9.